H.C. Wainwright analyst Ed Arce raised the firm’s price target on Akebia Therapeutics to $6 from $5 and keeps a Buy rating on the shares. The company announced last night that Vafseo has been approved by the FDA for the treatment of anemia due to chronic kidney disease in adult patients on dialysis, as has been widely expected, the analyst tells investors in a research note. The firm says Vafseo’s label is better than it expected. It expects Vafseo “to hit the ground running” upon full launch in January 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics Celebrates FDA Approval of Anemia Drug
- Biotech Alert: Searches spiking for these stocks today
- Akebia Therapeutics Confronts Financial Reporting Flaw: Inventory Management Weakness Sparks Investor Concern
- Akebia Therapeutics Announces CFO Transition and Interim Plan
- Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
